In a report released today, Jotin Marango from Roth Capital maintained a Buy rating on Aimmune Therapeutics (AIMT), with a price target of $80. The company’s shares opened today at $22.07, close to its 52-week low of $21.38.
Marango commented:
“We believe that the start of this study in infants (ages 1-3) following results from PALISADE (ages 4-17) is an indirect acknowledgement by the FDA of the positive risk/reward of AR101. Importantly, we see low risk to this study on the safety/efficacy front, based on the former DEVIL study of similar scope and design. Of note, the former PI of the DEVIL study is now the PI of Aimmune’s POSEIDON study. What did we learn from the DEVIL study? Despite its unorthodox name, in our view this study is the best reference frame for peanut desensitization in infants (read it here). Briefly, the data suggest that in this population OIT is squarely immunoregulatory: 29/37 (78%) of infants treated with OIT for a median of 29 months achieved sustained unresponsiveness 4 weeks after stopping treatment (i.e.”
According to TipRanks.com, Marango ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -19.5% and a 20.5% success rate. Marango covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Cyclacel Pharmaceuticals, and Actinium Pharmaceuticals.
Aimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $55.57, implying a 151.8% upside from current levels. In a report issued on December 12, Credit Suisse also maintained a Buy rating on the stock with a $40 price target.
.
See today’s analyst top recommended stocks >>
Based on Aimmune Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $51.7 million. In comparison, last year the company had a GAAP net loss of $31.79 million.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
